Hep C.
Seems this company is just stringing along investors. All things considered, they will be delisted from NASDAQ soon. It really is a shame, excusing management for questionable decisions over the last 4 years. This could have been a nice co-treatment with SOC IFN.
Rev: CELG
Secondary Cancers.
More to come.
Wednesday, August 31, 2011
Tuesday, August 23, 2011
New Postings!
I'm back and will post starting tomorrow.
I think an update to the hepatitis b drug in phase IIb from ANDS should wake up some old ghosts and get the blood pumping again.
8-23-2011---ANA598.
upcoming: an update on CELG pipeline of the blood cancer drug Revlimid.
stay tuned for some information!
I think an update to the hepatitis b drug in phase IIb from ANDS should wake up some old ghosts and get the blood pumping again.
8-23-2011---ANA598.
upcoming: an update on CELG pipeline of the blood cancer drug Revlimid.
stay tuned for some information!
Subscribe to:
Posts (Atom)
